MCK
NYSE · USDMcKesson Corporation
Healthcare · Medical - Distribution
CEO Brian S. Tyler
Employees 43,000
R&D / revenue 0.0%
Last price
$1,004.84+0.62%last session
Market cap
$117.2B
P/E (TTM)
26.8x
From 52w high
−1.0%
From 52w low
+38.9%
1-year return
+29.7%
RSI 14 · vs SMA200
75.8 · +17.7%
IS score
60.4/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)
One year, rebased to 100
MCK SPY XLV (sector ETF) · weekly closesScore DNA
Each bar is a 0-100 score within the scored universe8Profitability
75Growth
49Value
90Momentum
100Risk (safety)
58Quality
47Balance sheet
87Earnings quality
Flags
Strengths
✓ Piotroski 8+✓ FCF yield 5%+✓ Congress buying
Warnings
None of the computed warning flags fires for MCK (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Narrow, Efficient ScalePiotroski 8 / 9Altman Z 5.7Beta 0.312 of 4 smart-money sources active
Smart-money strip
Each disclosure source on its own window. Filings coinciding is not coordination.INSForm 4 · 180 days
Insider open-market buys
0
11 open-market sales, $24.0M
Form 144 notices (12m): 16, $35.0M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
4
Last disclosed purchase 2026-08-10
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
−29
172 new holders, 182 closed
2,016 filers hold 89.6% · 707 added, 805 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+25
1,190 funds adding shares
1,165 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
43.5%
20-day avg 53.2%, 50-day avg 56.2%
Latest 9.7 pp under its 20-day average · a flow, not short interest
Key financials · FY2026
USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.Income statement
Revenue$403.4B
Revenue growth YoY+12.4%
Gross margin3.6%
Operating income$6.5B
Operating margin1.6%
Net income$4.8B
Net margin1.2%
EPS (diluted)$38.38
Cash flow
Operating cash flow$6.2B
Capital expenditure$745.0M
Free cash flow$5.4B
FCF conversion (FCF / OCF)87.9%
Stock-based compensation$0
FCF less SBC$5.4B
Buybacks$4.8B
Dividends$381.0M
Balance sheet & returns
Cash & short-term investments$4.0B
Total debt$6.4B
Net debt$2.4B
Shareholders' equity−$834.0M
Goodwill & intangibles$15.4B
Debt / equity-2.76
ROE (TTM)-194.4%
ROIC (TTM)27.9%
Operating margin by fiscal year
Revenue $264.0B (FY2022) to $403.4B (FY2026), a 11.2% CAGR.
Valuation
P/E (TTM)26.8x
EV / EBITDA16.9x
Price / sales0.29x
Price / FCF18.9x
FCF yield5.28%
Buyback yield4.05%
SBC / revenue0.0%
Price / bookn/m
Forward P/E FY202722.5x
Forward P/E FY202819.8x
Forward multiples divide today's price by Street EPS estimates. Street mean target $995.00 across 6 analysts last quarter is theirs, not ours.
MCK vs industry median
42 companies in Medical - Distribution
MCK (TTM)Industry median
Asset turnover 4.65 vs industry 1.91 · financial leverage -20.83
Earnings delivery
Next report 2026-11-04 · consensus EPS $10.7283%
beat rate, 10 of 12 quarters
+2.3%
median EPS surprise
6
longest beat streak
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-11-01 to 2026-08-05. Bars cap at ±60%.
Peers
Market-cap band, not the industry cohort above| Company | Mkt cap | P/E | ROE | Net margin | Rev growth | 12m return |
|---|---|---|---|---|---|---|
| MCK McKesson Corporation | $117.2B | 26.8x | -194.4% | 1.1% | +12.4% | +29.7% |
| CAH Cardinal Health, Inc. | $58.8B | 34.9x | -60.5% | 0.6% | +14.2% | +67.3% |
| ABC AmerisourceBergen Corporatio | $36.1B | 13.3x | 103.9% | 0.9% | +2.9% | — |
| CVS CVS Health Corp. | $118.1B | 24.1x | 6.2% | 2.8% | +7.4% | +14.4% |
| MDT Medtronic Plc | $121.2B | 23.2x | 10.7% | 15.1% | +9.8% | +3.0% |
| SYK Stryker Corporation | $113.0B | 30.3x | 16.5% | 19.4% | +8.5% | −20.2% |
| BMY Bristol-Myers Squibb Company | $122.1B | 13.2x | 46.7% | 25.6% | +3.1% | — |
| VRTX Vertex Pharmaceuticals Incor | $126.7B | 28.9x | 23.5% | 33.0% | +10.6% | — |
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.
Recent 8-K filings
2026-10-06Regulation FD; Exhibits
2026-08-28Regulation FD; Exhibits
2026-08-05Earnings Release; Exhibits
2026-07-24Shareholder Vote
2026-07-01Officer/Director Change; Regulation FD; Exhibits
2026-06-12Material Agreement; Financial Obligation; Exhibits
Context
Shares outstanding116,590,363
Free float99.9%
Institutional ownership89.6%
Beta0.31
Dividend yield0.34%
Last dividend$0.94 on 2026-09-01
50 / 200-day average$893.76 / $853.09
Large-cap Healthcare median P/E29.7x
Full factsheet
The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Narrow).
Read it in the browser Download (PDF)All fundamentals · 140 measures in 13 categories
Percentile = where MCK sits among 5 scored companies in Medical - Distribution (0 = lowest value, 100 = highest). It is a position, not a grade.ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)
Valuation
| Measure | MCK | Industry percentile |
|---|---|---|
| P/E (TTM) | 25.5x | |
| PEG (P/E ÷ 3-yr EPS CAGR) | 2.13 | |
| Price / sales | 0.3x | 50th |
| Price / book | — | |
| Price / tangible book | — | |
| Price / free cash flow | 18.9x | |
| Price / operating cash flow | 17.1x | |
| Enterprise value | $123.7B | 100th |
| EV / sales | 0.3x | 50th |
| EV / EBITDA | 16.9x | |
| EV / EBIT | 18.8x | |
| EV / free cash flow | 20.0x | |
| Earnings yield | 3.9% | 50th |
| FCF yield | 5.3% | 25th |
| Operating cash flow yield | 5.8% | 25th |
| Graham number (per share) | — |
Profitability (TTM)
| Measure | MCK | Industry percentile |
|---|---|---|
| Gross margin | 3.6% | 25th |
| EBITDA margin | 1.8% | 75th |
| Operating margin | 1.6% | 75th |
| EBIT margin | 1.6% | 75th |
| Net margin | 1.1% | 75th |
| NOPAT margin | 1.3% | 75th |
| FCF margin | 1.5% | 50th |
| Operating cash flow margin | 1.7% | 50th |
| R&D / revenue | 0.0% | 0th |
| SG&A / revenue | 1.0% | 0th |
| Stock comp / revenue | 0.0% | 0th |
| Effective tax rate | 17.9% | 0th |
Returns on capital
| Measure | MCK | Industry percentile |
|---|---|---|
| ROE (on average equity) | — | |
| ROA | 5.4% | 100th |
| ROIC | 237.7% | 100th |
| ROCE | 36.6% | 100th |
| Return on tangible assets | 7.7% | 100th |
| Cash ROIC (OCF / invested capital) | 298.3% | 100th |
| Gross profitability (GP / assets) | 16.9% | 50th |
| ROIC, 3-yr average | 142.0% | |
| ROIC, 5-yr average | — | |
| ROE, 5-yr average | — | |
| Incremental ROIC | -567.2% | 0th |
Growth
| Measure | MCK | Industry percentile |
|---|---|---|
| Revenue growth (TTM YoY) | 8.8% | 50th |
| Revenue growth (QoQ) | 9.4% | 100th |
| Revenue CAGR, 3 yr | 13.1% | 100th |
| Revenue CAGR, 5 yr | 10.9% | 75th |
| Gross profit CAGR, 3 yr | 8.4% | |
| Operating income CAGR, 3 yr | 14.6% | |
| Net income growth (TTM YoY) | 45.1% | |
| Net income CAGR, 3 yr | 7.0% | |
| EPS growth (TTM YoY) | 52.8% | |
| EPS CAGR, 3 yr | 12.0% | |
| EPS CAGR, 5 yr | — | |
| FCF growth (TTM YoY) | 9.2% | |
| FCF CAGR, 3 yr | 11.5% | |
| Operating cash flow CAGR, 3 yr | 10.7% | |
| Book value CAGR, 3 yr | — | |
| Dividend CAGR, 3 yr | 8.5% | |
| Sustainable growth rate | — |
Margin history & stability
| Measure | MCK | Industry percentile |
|---|---|---|
| Gross margin, 3-yr average | 3.6% | 75th |
| Operating margin, 3-yr average | 1.3% | 75th |
| Net margin, 3-yr average | 1.0% | 75th |
| FCF margin, 3-yr average | 1.3% | 75th |
| Revenue stability (0-1) | 0.94 | 75th |
| Earnings stability (0-1) | 0.65 | 75th |
| Margin stability (0-1) | 0.85 | 25th |
Liquidity (latest quarter)
| Measure | MCK | Industry percentile |
|---|---|---|
| Cash & short-term investments | $5.2B | 100th |
| Net cash (− = net debt) | −$6.5B | 25th |
| Working capital | −$7.5B | 0th |
| Current ratio | 0.89 | 25th |
| Quick ratio | 0.52 | 25th |
| Cash ratio (cash + ST investments / current liabilities) | 0.07 | 75th |
| Defensive interval (days) | 1,560 days | 100th |
Leverage & solvency (latest quarter)
| Measure | MCK | Industry percentile |
|---|---|---|
| Total debt | $11.7B | 75th |
| Debt / equity | — | |
| Net debt / equity | — | |
| Debt / assets | 13.2% | 25th |
| Debt / capital | — | |
| Debt / EBITDA | 1.59 | |
| Net debt / EBITDA | 0.89 | |
| Interest coverage (EBIT / interest) | 43.0x | |
| Cash interest coverage | 44.8x | |
| Debt payback (years of OCF) | 1.7 yrs | |
| Liabilities / assets | 104.4% | 75th |
| IS credit model rating | AA+ | |
| Implied credit spread (bps) | 65 | 0th |
Efficiency
| Measure | MCK | Industry percentile |
|---|---|---|
| Asset turnover | 4.85 | 100th |
| Fixed asset turnover | 88.86 | 50th |
| Inventory turnover | 15.4 | 50th |
| Receivables turnover | 14.1 | 75th |
| Days sales outstanding | 26 days | 25th |
| Days inventory outstanding | 24 days | 50th |
| Days payables outstanding | 56 days | 75th |
| Cash conversion cycle (days) | −6 days | 50th |
| Capex / revenue | 0.2% | 25th |
| Capex / depreciation | 0.87 | 100th |
| Operating expense ratio | 2.2% | 0th |
Cash flow & earnings quality
| Measure | MCK | Industry percentile |
|---|---|---|
| Operating cash flow / net income | 1.49 | |
| FCF / net income | 1.35 | |
| FCF / operating cash flow | 90.3% | |
| Capex / operating cash flow | 9.7% | |
| Accruals ratio | -2.7% | 75th |
| Sloan accruals ratio | -0.9% | 75th |
| Earnings quality score (0-1) | 1.00 |
Scores & forensic checks
| Measure | MCK | Industry percentile |
|---|---|---|
| IS score | 60 | 100th |
| IS profitability | 8 | 50th |
| IS growth | 75 | 100th |
| IS value | 49 | 100th |
| IS momentum | 90 | 100th |
| IS risk (safety) | 100 | 25th |
| IS quality | 58 | 75th |
| IS balance sheet | 47 | 75th |
| IS earnings quality | 87 | 100th |
| IS cash flow | 59 | 25th |
| Piotroski F-score (0-9) | 8 | 75th |
| Altman Z-score | 5.7 | 75th |
| Beneish M-score | −2.53 | 100th |
| Ohlson O-score | −7.15 | 25th |
| IS credit score | 91 | 100th |
Size (TTM)
| Measure | MCK | Industry percentile |
|---|---|---|
| Market cap | $117.2B | 100th |
| Revenue | $411.0B | 100th |
| EBITDA | $7.3B | 100th |
| Net income | $4.6B | 100th |
| Free cash flow | $6.2B | 100th |
| Total assets | $88.3B | 100th |
| Shareholders' equity | −$4.2B | 0th |
| Employees | 42,300 | 50th |
Insider transactions, last 6 months
Form 4 · most recent 12| Date | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-08 | Rutledge Napoleon B Jr SVP, Controller & CAO |
Open-market sale | 111 | $891.45 | $98,951 | 521 |
| 2026-08-10 | Lerman Bradley E Director |
Open-market sale | 301 | $892.33 | $268,590 | 0 |
| 2026-08-07 | Srinivasan Ramesh (Nmn) EVP and Chief Strategy Officer |
Award / grant | 368 | — | — | 368 |
| 2026-08-01 | Srinivasan Ramesh (Nmn) EVP and Chief Strategy Officer |
— | 316 | — | — | 0 |
| 2026-07-22 | Hinton James H. Director |
Award / grant | 277 | — | — | 277 |
| 2026-07-22 | Doughtie Lynne M Director |
Award / grant | 277 | — | — | 277 |
| 2026-07-22 | Wilson-Thompson Kathleen Director |
Award / grant | 277 | $814.04 | $225,489 | 578 |
| 2026-07-22 | Dunbar Webster Roy Director |
Award / grant | 277 | — | — | 277 |
| 2026-07-22 | Caruso Dominic J Director |
Award / grant | 277 | $814.04 | $225,489 | 927 |
| 2026-07-22 | Gerberding Julie L. Director |
Award / grant | 277 | — | — | 277 |
| 2026-07-22 | Lerman Bradley E Director |
Award / grant | 277 | — | — | 277 |
| 2026-07-22 | Martinez Maria Director |
Award / grant | 277 | $814.04 | $225,489 | 578 |
Shares acquired vs disposed, by month
acquired disposed · all Form 4 typesBy transaction type, 6 months
| Type | Direction | Filings | Shares | Value |
|---|---|---|---|---|
| Award / grant | Acquired | 27 | 83,078 | $676,467 |
| Open-market sale | Disposed | 11 | 30,970 | $24.0M |
| Option exercise | Disposed | 20 | 20,787 | — |
| Option exercise | Acquired | 20 | 20,787 | — |
| Tax withholding | Disposed | 28 | 28,164 | $21.5M |
| — | Disposed | 3 | 316 | — |
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.
Form 144 notices
12 months: 16 notices · 43,295 shares · $35.0M| Filed | Filer | Shares proposed | Est. proceeds |
|---|---|---|---|
| 2026-10-15 | Fraga Francisco | 801 | $797,129 |
| 2026-08-10 | Lerman Bradley E | 301 | $268,589 |
| 2026-08-03 | Vitalone Britt J. | 7,925 | $6.7M |
| 2026-07-07 | Tyler Brian S. | 8,463 | $6.7M |
A Form 144 is notice of a proposed sale, not a confirmed one.
Congress trades
12 months: House 21 trades (13 purchases) · Senate 5 (5 purchases)| Traded | Member | Chamber | Type | Amount | Disclosed |
|---|---|---|---|---|---|
| 2026-08-10 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-09-07 |
| 2026-07-08 | Rick Larsen | House | Purchase | $1,001 - $15,000 | 2026-07-13 |
| 2026-07-08 | Richard Ray Larsen | House | Purchase | $1,001 - $15,000 | 2026-07-13 |
| 2026-07-07 | Richard Ray Larsen | House | Purchase | $1,001 - $15,000 | 2026-07-13 |
| 2026-02-04 | Markwayne Mullin | Senate | Purchase | $15,001 - $50,000 | 2026-03-02 |
| 2026-01-05 | Markwayne Mullin | Senate | Purchase | $15,001 - $50,000 | 2026-02-04 |
| 2026-01-05 | Markwayne Mullin | Senate | Purchase | $15,001 - $50,000 | 2026-02-04 |
| 2026-01-05 | Markwayne Mullin | Senate | Purchase | $15,001 - $50,000 | 2026-02-03 |
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.
Largest 13F holders
Quarter to 2026-06-30, the latest most managers have filed| Manager | Shares | Value | % of shares out |
|---|---|---|---|
| BlackRock, Inc. | 10,795,054 | $8.2B | 9.26% |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,853,137 | $5.9B | 6.74% |
| STATE STREET CORP | 5,727,118 | $4.3B | 4.91% |
| MORGAN STANLEY | 3,306,807 | $2.5B | 2.84% |
| FRANKLIN RESOURCES INC | 2,905,041 | $2.2B | 2.49% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,873,217 | $2.2B | 2.46% |
| GEODE CAPITAL MANAGEMENT, LLC | 2,822,155 | $2.1B | 2.42% |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2,446,386 | $1.9B | 2.10% |
| FMR LLC | 2,130,288 | $1.6B | 1.83% |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,551,950 | $1.2B | 1.33% |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 1,538,910 | $1.2B | 1.32% |
| NORGES BANK | 1,529,056 | $1.2B | 1.31% |
| JPMORGAN CHASE & CO | 1,471,558 | $1.1B | 1.26% |
| BANK OF AMERICA CORP /DE/ | 1,321,991 | $998.9M | 1.13% |
| GOLDMAN SACHS GROUP INC | 1,321,129 | $998.2M | 1.13% |
Institutional ownership by quarter
% of shares held by 13F filers
Number of 13F filers holding
Holder changes by quarter
| Quarter | Holders | Ownership | New | Increased | Reduced | Closed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 2,016 | 89.6% | 172 | 707 | 805 | 182 |
| 2026-03-31 | 2,045 | 90.1% | 194 | 722 | 796 | 117 |
| 2025-12-31 | 2,000 | 91.7% | 297 | 700 | 670 | 85 |
| 2025-09-30 | 1,828 | 90.2% | 168 | 639 | 668 | 101 |
| 2025-06-30 | 1,790 | 93.0% | 174 | 631 | 666 | 109 |
| 2025-03-31 | 1,753 | 92.8% | 228 | 603 | 630 | 111 |
| 2024-12-31 | 1,666 | 92.0% | 257 | 548 | 627 | 97 |
| 2024-09-30 | 1,543 | 93.0% | 111 | 516 | 659 | 175 |
| 2024-06-30 | 1,631 | 94.1% | 161 | 644 | 548 | 73 |
| 2024-03-31 | 1,560 | 94.1% | 173 | 557 | 582 | 70 |
| 2023-12-31 | 1,479 | 95.3% | 235 | 486 | 540 | 79 |
| 2023-09-30 | 1,343 | 96.2% | 120 | 450 | 522 | 76 |
Schedule 13D / 13G filers
| Filed | Form | Filer | % of class | Shares |
|---|---|---|---|---|
| 2026-04-30 | SCHEDULE 13G | Vanguard Capital Management | 7.5% | 9,180,981 |
| 2026-03-27 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 |
| 2025-04-17 | SCHEDULE 13G/A | BlackRock, Inc. | 7.3% | 9,207,960 |
Required above 5% of a class; 13G is the passive form.
ETFs with the largest holding
| ETF | Weight in fund | Holding value |
|---|---|---|
| VITSX | 0.14% | $3.2B |
| VTSAX | 0.14% | $3.2B |
| VSMPX | 0.14% | $3.2B |
| VTI | 0.14% | $3.2B |
| VFFSX | 0.15% | $2.6B |
| VFINX | 0.15% | $2.6B |
Share structure
Shares outstanding116,590,363
Float116,515,149
Free float99.9%
Income statement
Fiscal years, USD| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Revenue | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Cost of revenue | $251.3B | $264.8B | $296.7B | $346.6B | $388.9B |
| Gross profit | $12.6B | $11.9B | $12.2B | $12.5B | $14.6B |
| R&D | $70.0M | $89.0M | $77.0M | $91.0M | $103.0M |
| SG&A | $9.9B | $7.3B | $8.2B | $8.0B | −$8.1B |
| Operating income | $2.7B | $4.5B | $3.9B | $4.4B | $6.5B |
| EBITDA | $3.1B | $5.7B | $4.7B | $5.3B | $7.2B |
| Pretax income | $1.9B | $4.6B | $3.8B | $4.4B | $6.2B |
| Income tax | $636.0M | $905.0M | $629.0M | $878.0M | $1.1B |
| Net income | $1.1B | $3.6B | $3.0B | $3.3B | $4.8B |
| EPS, diluted | $7.23 | $25.04 | $22.39 | $25.72 | $38.38 |
| Diluted shares | 154.1M | 142.2M | 134.1M | 128.1M | 124.1M |
Balance sheet
| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Cash & short-term investments | $3.5B | $4.7B | $4.6B | $5.7B | $4.0B |
| Receivables | $18.6B | $19.4B | $21.6B | $25.6B | $28.0B |
| Inventory | $18.7B | $19.7B | $21.1B | $23.0B | $24.2B |
| Total current assets | $46.2B | $44.3B | $48.0B | $55.4B | $57.2B |
| PP&E, net | $3.6B | $3.8B | $4.0B | $4.3B | $4.7B |
| Goodwill & intangibles | $11.5B | $12.2B | $12.2B | $11.5B | $15.4B |
| Total assets | $63.3B | $62.3B | $67.4B | $75.1B | $82.3B |
| Accounts payable | $38.1B | $42.5B | $47.1B | $55.3B | $60.0B |
| Total current liabilities | $48.5B | $48.0B | $52.4B | $61.6B | $67.0B |
| Long-term debt | $5.1B | $4.6B | $5.6B | $4.5B | $5.1B |
| Total liabilities | $65.1B | $63.8B | $69.0B | $76.8B | $83.2B |
| Shareholders' equity | −$1.8B | −$1.5B | −$1.6B | −$1.7B | −$834.0M |
Cash flow statement
Outflows are negative| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Net income | $1.3B | $3.7B | $3.2B | $3.5B | $4.8B |
| Depreciation & amortization | $760.0M | $608.0M | $635.0M | $636.0M | $729.0M |
| Stock-based compensation | $161.0M | $162.0M | $0 | $0 | $0 |
| Change in working capital | $82.0M | $384.0M | −$64.0M | $1.2B | $162.0M |
| Operating cash flow | $4.4B | $5.2B | $4.3B | $6.1B | $6.2B |
| Capital expenditure | −$535.0M | −$558.0M | −$687.0M | −$859.0M | −$745.0M |
| Free cash flow | $3.9B | $4.6B | $3.6B | $5.2B | $5.4B |
| Investing cash flow | −$89.0M | −$542.0M | −$1.1B | −$733.0M | −$3.4B |
| Net debt issued / repaid | −$1.1B | −$277.0M | $56.0M | −$21.0M | $783.0M |
| Buybacks | −$3.5B | −$3.6B | −$3.0B | −$3.1B | −$4.8B |
| Dividends paid | −$277.0M | −$292.0M | −$314.0M | −$345.0M | −$381.0M |
Ratio history
Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Gross margin | 4.8% | 4.3% | 3.9% | 3.4% | 3.6% |
| Operating margin | 1.0% | 1.6% | 1.3% | 1.1% | 1.6% |
| Net margin | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% |
| FCF margin | 1.5% | 1.7% | 1.2% | 1.5% | 1.3% |
| ROE | -97.2% | -172.4% | -156.8% | -162.9% | -224.3% |
| ROIC | 100.0% | 471.4% | 391.8% | -879.3% | 212.4% |
| ROA | 1.7% | 5.7% | 4.6% | 4.6% | 6.0% |
| Debt / equity | -3.32 | -3.93 | -3.75 | -3.56 | -3.97 |
| Interest coverage | 11.8x | 19.7x | 16.6x | 18.0x | 50.3x |
| Current ratio | 0.95 | 0.92 | 0.92 | 0.90 | 0.85 |
| Revenue growth | +10.8% | +4.8% | +11.7% | +16.2% | +12.4% |
| EPS growth | +126.4% | +245.5% | −11.6% | +14.7% | +48.3% |
| P/E at year end | 40.2x | 13.6x | 23.4x | 25.6x | 22.3x |
| EV / EBITDA at year end | 15.7x | 8.9x | 15.6x | 16.4x | 15.8x |
| FCF yield at year end | 8.70% | 9.49% | 5.17% | 6.19% | 5.10% |
| Dividend payout | 24.9% | 8.2% | 10.5% | 10.5% | 8.0% |
Revenue by segment
| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| North American Pharmaceutical Segment | — | — | — | — | $336.7B |
| U.S. Pharmaceutical Segment | $212.1B | $240.6B | $278.7B | $327.7B | — |
| Oncology And Multispecialty Segment | — | — | — | — | $48.4B |
| International Segment | $36.3B | $20.6B | $14.1B | $14.7B | — |
| Medical-Surgical Solutions Segment | $11.6B | $11.1B | $11.3B | $11.4B | $11.5B |
| Prescription Technology Solutions Segment | — | — | — | — | $5.8B |
| Prescription Technology Solutions | $3.9B | $4.4B | $4.8B | $5.2B | — |
| Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment | — | — | — | — | $1.0B |
Street estimates by fiscal year
Next report 2026-11-04 · consensus EPS $10.72 · these are analysts' numbers, not ours| Fiscal year | Revenue (mean) | Revenue range | EPS (mean) | EPS range | Analysts | P/E on mean EPS |
|---|---|---|---|---|---|---|
| 2026 | $408.5B | $407.4B – $411.5B | $39.01 | $38.96 – $39.09 | 10 | 25.8x |
| 2027 | $431.9B | $410.1B – $435.9B | $44.65 | $44.26 – $45.19 | 9 | 22.5x |
| 2028 | $461.3B | $433.6B – $477.8B | $50.67 | $47.41 – $51.48 | 8 | 19.8x |
Reported vs expected, every quarter on file
| Reported | EPS expected | EPS actual | EPS surprise | Revenue expected | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|
| 2026-08-05 | $9.56 | $9.93 | +3.9% | $103.9B | $105.4B | +1.4% |
| 2026-05-07 | $11.56 | $11.69 | +1.1% | $101.3B | $96.3B | −5.0% |
| 2026-02-04 | $9.17 | $9.34 | +1.9% | $105.8B | $106.2B | +0.3% |
| 2025-11-05 | $9.03 | $9.86 | +9.2% | $104.1B | $103.2B | −0.9% |
| 2025-08-06 | $8.14 | $8.26 | +1.5% | $96.2B | $97.8B | +1.7% |
| 2025-05-08 | $9.83 | $10.12 | +3.0% | $94.3B | $90.8B | −3.7% |
| 2025-02-05 | $8.60 | $8.03 | −6.6% | $96.1B | $95.3B | −0.8% |
| 2024-11-06 | $6.88 | $7.07 | +2.8% | $89.3B | $93.7B | +4.8% |
| 2024-08-07 | $7.21 | $7.88 | +9.3% | $82.5B | $79.3B | −3.9% |
| 2024-05-07 | $6.34 | $6.18 | −2.5% | $79.3B | $76.4B | −3.7% |
| 2024-02-07 | $7.04 | $7.74 | +9.9% | $77.9B | $80.9B | +3.8% |
| 2023-11-01 | $6.15 | $6.23 | +1.3% | $76.0B | $77.2B | +1.7% |
| 2023-08-02 | $5.87 | $7.27 | +23.9% | $70.3B | $74.5B | +6.0% |
| 2023-05-08 | $7.17 | $7.19 | +0.3% | $68.1B | $68.9B | +1.2% |
| 2023-02-01 | $6.35 | $6.90 | +8.7% | $71.0B | $70.5B | −0.8% |
| 2022-11-01 | $6.09 | $6.06 | −0.5% | $70.2B | $70.2B | −0.1% |
| 2022-08-03 | $5.28 | $5.83 | +10.4% | $64.9B | $67.2B | +3.4% |
| 2022-05-05 | $6.06 | $5.83 | −3.8% | $63.7B | $66.1B | +3.8% |
| 2022-02-02 | $5.38 | $6.15 | +14.3% | $66.6B | $68.6B | +3.0% |
| 2021-11-01 | $4.67 | $6.15 | +31.7% | $63.2B | $66.6B | +5.3% |
| 2021-08-04 | $4.09 | $5.56 | +35.9% | $62.7B | $62.7B | 0.0% |
| 2021-05-06 | $5.04 | $5.05 | +0.2% | $59.0B | $59.1B | +0.2% |
| 2021-02-02 | $4.13 | $4.60 | +11.4% | $55.5B | $62.6B | +12.8% |
| 2020-11-03 | $3.87 | $4.80 | +24.0% | $4.1B | $60.8B | +1,366.7% |
Off-exchange (dark pool) volume, weekly
FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)| Week of | Notional | Shares | Trades |
|---|---|---|---|
| 2026-08-31 | $825.4M | 906,887 | 47,969 |
| 2026-08-24 | $1.1B | 1,192,926 | 53,975 |
| 2026-08-17 | $879.7M | 1,019,106 | 56,949 |
| 2026-08-10 | $1.1B | 1,286,227 | 61,619 |
| 2026-08-03 | $1.5B | 1,798,855 | 64,077 |
| 2026-07-27 | $1.0B | 1,168,703 | 51,870 |
Short-sale share of off-exchange volume
daily 20-day average| Date | Short share | Short volume | Total volume |
|---|---|---|---|
| 2026-10-15 | 43.5% | 136,459 | 313,378 |
| 2026-10-14 | 46.4% | 139,235 | 299,908 |
| 2026-10-13 | 48.5% | 122,915 | 253,286 |
| 2026-10-12 | 61.6% | 157,420 | 255,648 |
| 2026-10-09 | 61.4% | 115,692 | 188,488 |
| 2026-10-08 | 56.4% | 156,166 | 277,001 |
| 2026-10-07 | 38.9% | 144,131 | 370,992 |
| 2026-10-06 | 57.9% | 148,842 | 257,188 |
| 2026-10-05 | 53.7% | 126,246 | 235,097 |
| 2026-10-02 | 59.0% | 183,295 | 310,552 |
A daily flow measure from FINRA, not short interest.
Seasonality
Average return by calendar month| Month | Avg return | Up years | Years |
|---|---|---|---|
| Jan | +2.8% | 80% | 20 |
| Feb | +1.0% | 55% | 20 |
| Mar | +0.0% | 52% | 21 |
| Apr | +0.9% | 60% | 20 |
| May | +6.3% | 90% | 20 |
| Jun | +0.1% | 45% | 20 |
| Jul | +0.8% | 50% | 20 |
| Aug | −1.7% | 40% | 20 |
| Sep | −0.5% | 45% | 20 |
| Oct | +0.8% | 65% | 20 |
| Nov | +4.4% | 85% | 20 |
| Dec | +0.8% | 40% | 20 |
History, not a forecast.
Indicators
as of 2026-10-16RSI 1475.8
MFI73.4
ADX29.2
Stochastic %K / %D96.7 / 96.6
Williams %R-4.5
CCI169
TSI / signal31.8 / 16.4
Chaikin money flow0.05
ATR$22.25
Bollinger width19.8%
Volume vs 20-day avg0.62x
SupertrendUp
Moving averages and bands
level (price vs level)SMA 20$914.24 (+9.9%)
SMA 50$896.25 (+12.1%)
SMA 200$853.75 (+17.7%)
EMA 21$929.55 (+8.1%)
EMA 50$897.89 (+11.9%)
EMA 200$843.48 (+19.1%)
Bollinger upper$1,004.53 (+0.0%)
Bollinger lower$823.95 (+22.0%)
Parabolic SAR$926.06 (+8.5%)
Open the live chart, 110+ indicatorsAbout McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
https://www.mckesson.com
Key executives
| Name | Title | Pay | Born |
|---|---|---|---|
| Brian S. Tyler | CEO & Chairman | $7.0M | 1967 |
| Kenny K. Cheung | Executive Vice President & Chief Financial Officer | $2.7M | 1982 |
| Michele Lau | Executive Vice President & Chief Legal Officer | $1.9M | 1976 |
| LeAnn Smith | Executive Vice President & Chief Human Resources Officer | $1.8M | 1975 |
| Francisco Fraga | Executive Vice President, Chief Information Officer & Chief Technology Officer | — | 1973 |
| Jeni Dominguez | Head of Investor Relations | — | — |
| Kirk Kaminsky | Executive Vice President & Group President of North American Pharmaceutical Services | — | — |
| Napoleon Rutledge Jr. | Senior Vice President, Controller & Chief Accounting Officer | — | 1973 |
Executive pay, latest proxy
| Executive | Year | Salary | Stock awards | Incentive | Total |
|---|---|---|---|---|---|
| Brian S. Tyler Chief Executive Officer | 2026 | $1.6M | $17.2M | $4.5M | $24.2M |
| Britt J. Vitalone Executive Vice President and Chief Financial Officer | 2026 | $1.1M | $5.6M | $1.9M | $8.7M |
| Michele Lau Executive Vice President and Chief Legal Officer | 2026 | $766,583 | $3.7M | $1.1M | $5.6M |
| LeAnn B. Smith Executive Vice President and Chief Human Resources Officer | 2026 | $693,833 | $2.5M | $971,366 | $4.3M |
| Thomas L. Rodgers Executive Vice President and Chief Strategy and Business Development Officer | 2026 | $647,450 | $1.8M | $906,430 | $3.4M |
Employees
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| 2026-09-01 | $0.94 | 2026-10-01 |
| 2026-06-01 | $0.82 | 2026-07-01 |
| 2026-03-02 | $0.82 | 2026-04-01 |
| 2025-12-01 | $0.82 | 2026-01-02 |
| 2025-09-02 | $0.82 | 2025-10-01 |
| 2025-06-02 | $0.71 | 2025-07-01 |
| 2025-03-03 | $0.71 | 2025-04-01 |
| 2024-12-02 | $0.71 | 2025-01-02 |
Moat model
Narrow · Efficient Scale · 2026-06-30Cost advantage66
Intangibles43
Switching costs55
Network effect70
Efficient scale80
Our component scores (0-100) and overall 60.2; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17